Hepatitis cases in children linked to adeno-associated virus AAV2

Pediatrician checking little girl throat in clinic

Recent acute hepatitis cases of unknown origin in children have now been linked to the adeno-associated virus 2 (AAV2) in two new UK studies.

There was no evidence of a direct link to SARS-CoV-2 infection.

Submitted to MedRxiv as pre-prints, both studies found that the common virus AAV2 was present at high levels in all samples from patients with unexplained hepatitis.

The virus is not known to normally cause disease and often accompanies infection with adenoviruses.

It has now been found by scientists to be associated with the development of acute hepatitis in a small number of young children.

Independent, simultaneous studies

The two studies were led independently and simultaneously:

Since April 2022, a number of young children worldwide have developed jaundice and acute severe hepatitis of unknown origin.

1,010 cases in 35 countries

Currently the WHO has reported at least 1,010 probable cases in 35 countries.

Children with the condition have commonly had to be hospitalised for a number of days, with 11 children in England and one in Scotland requiring a liver transplant.

In the UK, the majority of the 268 cases have been under the age of five years old with nearly 40% of hospitalised cases (74 of 189) requiring admission to intensive care.

What is causing the spike?

Previously, health officials had thought that a spike in adenovirus infections in spring 2022 may be part of the explanation for this spike in hepatitis cases.

Until now adenovirus was the most commonly found virus in samples from the affected children.

These two new studies shed light on another virus that seems to play a significant role.

Researchers across two teams found that AAV2 was present in 96% cases of unknown hepatitis examined across both studies.

AAV2 cannot replicate without a ‘helper’ virus such as an adenovirus or herpesvirus.

Therefore, the researchers believe that the best explanation for the onset of severe liver disease in affected children is coinfection with two viruses. This involves AAV2 and an adenovirus, or less often the herpes virus HHV6 (which has also been found in sample from some patients).

The Glasgow research and patient genetics

The Scottish study carried out a detailed investigation of nine cases and 58 control subjects.

Using next-generation sequencing and real-time polymerase chain reaction, the research team compared samples and were able to confirm the presence of AAV2 in the plasma and liver of all nine cases.

There was no AAV2 in any of the subjects in the control groups, which were made up of:

  • age-matched healthy controls
  • children with adenovirus but normal liver function
  • children admitted to hospital with known causes of hepatitis.

Patients with unknown hepatitis

The Scottish study also examined the genetics of the patients with unknown hepatitis. This was alongside the pathogen genomics, to find out whether any of the children may be more susceptible to this type of acute hepatitis.

Using detailed genomic testing of the patients, researchers were able to identify differences in the human leukocyte antigen gene.

The gene was not commonly found in the control groups of healthy children, or in the genes of children with other forms of hepatitis.

The team believe these genetic sequences may offer another part of the answer as to why some children have become seriously unwell.

Many unanswered questions

Professor Emma Thomson, from the MRC-University of Glasgow Centre for Virus Research and senior author of the Scottish study said:

The presence of the AAV2 virus is associated with unexplained hepatitis in children.

This virus can only infrequently in the presence of another virus (usually an adenovirus).

AAV2 may cause disease itself or it may be a useful biomarker of recent adenovirus infection, which may be the main underlying pathogen, but which can be harder to detect.

There are many unanswered questions and larger studies are urgently needed to investigate the role of AAV2 in paediatric hepatitis cases.

We also need to understand more about seasonal circulation of AAV2, a virus that is not routinely monitored.

It may be that a peak of adenovirus infection has coincided with a peak in AAV2 exposure, leading to an unusual manifestation of hepatitis in susceptible young children.

Preceding illnesses

Dr Antonia Ho, from the MRC-University of Glasgow Centre for Virus Research, said:

It is critical to interpret our findings in relation to the timeframe of the patients’ clinical presentation.

Most of the Scottish children had a preceding illness with diarrhoea, vomiting and abdominal pain (often associated with adenovirus infection) between one to 11 weeks prior to presenting to hospital with acute liver inflammation, which may explain why adenovirus has not been identified in all affected children.

The temporal association between adenovirus or HHV6 and AAV2 infections requires further study.

Rapid collaboration

Dr Anna Kinsey, Head of Epidemic Preparedness at the Medical Research Council (MRC), which part-funded the study, said:

This project is an excellent example of how rapid collaboration between leading virology and clinical experts at the MRC-University of Glasgow Centre for Virus Research and MRC-supported ISARIC-4C, and public health agencies is uncovering the likely cause of the recent outbreak of acute viral hepatitis in young children.

These two studies pave the way towards understanding why these children have become severely unwell.

The London research, sequencing and immunocompromised patients

With expertise in metagenomics and adenovirus sequencing, the London team studied 28 cases, including:

  • liver samples from five children that required a transplant
  • blood samples from the remaining children who did not.

Residual samples were sufficient to test 17 cases for AAV2, 16 of which tested positive.

RNA sequencing of liver samples confirmed the presence of AAV2 replication in the liver of children with unknown hepatitis.

Patient samples were compared with 132 controls from immunocompromised and immunocompetent patients.

The London study showed that AAV2 was present only very rarely in the children who did not have hepatitis (six out of 100) and at much lower levels, even for immunocompromised children (11 out of 32).

Role of co-infections

Professor Judy Breuer, from UCL GOS ICH and GOSH said:

While we still have some unanswered questions about exactly what led to this spike in acute hepatitis, we hope these results can reassure parents concerned about COVID-19 as neither teams have found any direct link with SARS-CoV-2 infection.

Our data do, however, point to AAV2 in the liver and, or blood of cases as the strongest biomarker for the hepatitis.

Additionally, the presence of HHV6 and adenovirus in the damaged livers, removed from the five children who needed liver transplants, raises questions as to the role of co-infections with these three viruses in the most severe cases.

We at GOSH and UCL were very happy to contribute our specialist expertise, which has been built-up to support children at GOSH, to help in the investigation of this global emergency, affecting children in the UK at the moment.

Unknown hepatitis and SARS-CoV-2

Both studies were able to rule out the likelihood of recent or prior SARS-CoV-2 infection as a direct cause for the acute hepatitis.

Researchers found no SARS-CoV-2 in the liver of patients.

Tests were conducted by the team in Glasgow to find out whether the children had previously had COVID-19.

They found that only two-thirds of the patients had antibodies to the infection, similar to SARS-CoV-2 antibody prevalence in Scottish children at the time.

Further, the peak in cases occurred well after the peak in COVID-19 cases in Scotland but only shortly after a peak in adenovirus infections.

Researchers still cannot be certain why this is happening now.

But both teams have highlighted the possibility that a peak in adenovirus infections in the general population after a period of lockdown may have contributed to this. This is through lowered immunity in children to certain viruses and changes in patterns of virus circulation.

Further information

To provide rapid information on this situation, the preliminary results are being made available as a preprints on medRxiv:

Full results will be submitted to peer-reviewed journals.

Top image:  Credit: Tomwang112, iStock, Getty Images Plus via Getty Images

This is the website for UKRI: our seven research councils, Research England and Innovate UK. Let us know if you have feedback or would like to help improve our online products and services.